Jane Street
NTLA icon

Jane Street’s Intellia Therapeutics NTLA Stock Holding History

Jane Street’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.07M Buy
551,400
+202,800
+58% +$2.58M ﹤0.01% 2996
2025
Q4 		$3.13M Buy
348,600
+322,800
+1,251% +$4.44M ﹤0.01% 3970
2025
Q3 		$446K Buy
25,800
+6,400
+33% +$78.8K ﹤0.01% 8103
2025
Q2 		$182K Sell
19,400
-18,700
-49% -$154K ﹤0.01% 8623
2025
Q1 		$271K Sell
38,100
-35,100
-48% -$355K ﹤0.01% 7969
2024
Q4 		$854K Buy
73,200
+2,400
+3% +$37.5K ﹤0.01% 5683
2024
Q3 		$1.45M Sell
70,800
-11,000
-13% -$254K ﹤0.01% 5112
2024
Q2 		$1.83M Buy
81,800
+41,900
+105% +$998K ﹤0.01% 4640
2024
Q1 		$1.1M Buy
39,900
+12,000
+43% +$333K ﹤0.01% 5245
2023
Q4 		$851K Sell
27,900
-700
-2% -$20.1K ﹤0.01% 5857
2023
Q3 		$904K Sell
28,600
-10,000
-26% -$388K ﹤0.01% 5328
2023
Q2 		$1.57M Sell
38,600
-22,200
-37% -$900K ﹤0.01% 4522
2023
Q1 		$2.27M Buy
60,800
+34,300
+129% +$1.35M ﹤0.01% 3600
2022
Q4 		$925K Sell
26,500
-29,500
-53% -$1.4M ﹤0.01% 5101
2022
Q3 		$3.13M Buy
56,000
+8,000
+17% +$496K ﹤0.01% 3374
2022
Q2 		$2.48M Sell
48,000
-34,800
-42% -$1.77M ﹤0.01% 3764
2022
Q1 		$6.02M Sell
82,800
-13,500
-14% -$1.14M ﹤0.01% 2724
2021
Q4 		$11.4M Sell
96,300
-300
-0.3% -$37.6K ﹤0.01% 1731
2021
Q3 		$13M Sell
96,600
-263,100
-73% -$39.8M ﹤0.01% 1493
2021
Q2 		$58.2M Buy
359,700
+266,900
+288% +$20.8M 0.02% 475
2021
Q1 		$7.45M Sell
92,800
-42,900
-32% -$2.88M ﹤0.01% 1885
2020
Q4 		$7.38M Buy
+135,700
New +$4.93M ﹤0.01% 1694
2020
Q3 		– Sell
-79,300
Closed -$1.67M – 7673
2020
Q2 		$1.67M Buy
+79,300
New +$1.35M ﹤0.01% 3312

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street's NTLA Position: Q1 2026 in Review

Jane Street increased its Intellia Therapeutics (NTLA) stake by 16% in Q1 2026, buying an estimated $669K and bringing the position to 384,957 shares worth $4.94M. The position accounts for ﹤0.01% of the portfolio, ranked #3540.

Jane Street first reported a position in NTLA in Q2 2020 and has held it in 24 quarters since. The position peaked at $8.37M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Jane Street held 384,957 shares of Intellia Therapeutics worth $4.94M as of Q1 2026.
  • Jane Street bought 52,486 Intellia Therapeutics shares in Q1 2026, an estimated $669K.
  • Intellia Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3540 holding.
  • Jane Street first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Jane Street's Intellia Therapeutics position peaked at $8.37M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.